Build status - In Progress

MT-3921- Phase 2 Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury

MT-3921- Phase 2 Study to Assess the Efficacy and Safety of MT-3921 in Subjects with Acute Traumatic Cervical Spinal Cord Injury
Recruiting
18 years - 70 years
All
Phase 2
3 participants needed
1 Location

Brief description of study

MT-3921 is an investigational monoclonal antibody therapy for patients with severe (AIS grade A-C) traumatic cervical spinal cord injury (SCIs). This study aims to compare the efficacy of MT-3921 to a placebo with regard to improving patients sensory and motor function and overall quality of life. Additionally this study aims to understand and characterize the safety and pharmacokinetic profiles of MT-3921 in the SCI population.

Participants will be identified through the following avenues: the trauma bay or NeuroICU of Penn Presbyterian Medical Center upon admission B) Arrive as transfers from outside hospitals, or C) Elect to receive care at Penn Presbyterian upon hearing about this clinical trial. Patients with recent (within 48 hours post-injury) and C4-C7 neurological level of injury (NLI) spinal cord injury (SCI) will be screened for participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: spinal cord injury
  • Age: 18 years - 70 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 848764

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center